OPRX•benzinga•
OptimizeRx Reaffirms FY22 Guidance, Sales $80M-$85M Vs 81.83M Est.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 4, 2022 by benzinga